Novel IO (investigational immuno-oncology agent)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Novel IO (investigational immuno-oncology agent), covering 2024-05-30 to 2024-05-30. Get the full timeline:
Most recent: Clinical Trial Update: Pre-operative Trial for Breast Cancer With Nivolumab in Combination With Novel IO [Phase 2]